Previously, a case report revealed an exceptional sorafenib response with near-complete tumor regression in a lung adenocarcinoma patient with an ARAF p.S214C mutation [14], suggesting the potential therapeutic value of this well-characterized multi-kinase inhibitor for lung cancer patients with ARAF mutations. This evidence concerns the gene ARAF and lung adenocarcinoma.